These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33371704)

  • 1. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic.
    Suárez Ferrer C; Pérez Robles T; Martín-Arranz MD
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154. PubMed ID: 33371704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Verma AM; Patel A; Subramanian S; Smith PJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
    [No Abstract]   [Full Text] [Related]  

  • 3. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases.
    Moran K; Null K; Huang Z; Lissoos T; Kane S
    Adv Ther; 2019 Sep; 36(9):2260-2272. PubMed ID: 31385283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
    Hilley P; Wong D; Ma R; Peterson A; De Cruz P
    Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
    Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
    Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
    J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organising infusions: Application administration and complications.
    Collins G
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():26. PubMed ID: 27273034
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar and innovator anti-Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?
    Gearry RB
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():24-5. PubMed ID: 27273033
    [No Abstract]   [Full Text] [Related]  

  • 15. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
    Afzali A; Ogden K; Friedman ML; Chao J; Wang A
    J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
    Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Bowel Disease in the COVID-19 Pandemic: the Patients' Perspective.
    Grunert PC; Reuken PA; Stallhofer J; Teich N; Stallmach A
    J Crohns Colitis; 2020 Dec; 14(12):1702-1708. PubMed ID: 32564068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.